As a response to the ongoing COVID-19 pandemic, in June 2020 EIT Health awarded close to €7 million in funding to 15 projects to help combat the COVID-19 pandemic as part of its Rapid Response initiative. One of those projects is CoViproteHCt, which aims to develop and validate assays to characterise protective immune responses that can be used to identify individuals with COVID-19 immunity. Led by TU Munich in cooperation with Fundación privada Instituto de Salud Global Barcelona (ISGLOBAL), University of Barcelona and Mikrogen GmbH, the project focuses initially on healthcare professionals working with COVID-19 patients and other critical areas, however, the assays can be adapted by companies and academic partners throughout the world within weeks. This approach will allow the selective release of individuals from quarantine restrictions and return to work, thus stabilising healthcare systems and the economy.
The full article with Professor Markus Gerhard of the TUM School of Medicine (pdf) is available here.